{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T15:12:06Z","timestamp":1769958726552,"version":"3.49.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,10,13]],"date-time":"2015-10-13T00:00:00Z","timestamp":1444694400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,10,13]],"date-time":"2015-10-13T00:00:00Z","timestamp":1444694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Erythropoietin (EPO) has been identified as being crucial for obesity modulation; however, its erythropoietic activity may limit its clinical application. EPO-derived Helix B-surface peptide (pHBSP) is nonerythrogenic but has been reported to retain other functions of EPO. The current study aimed to evaluate the effects and potential mechanisms of pHBSP in obesity modulation. We found that pHBSP suppressed adipogenesis, adipokine expression and peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3) levels during 3T3-L1 preadipocyte maturation through the EPO receptor (EPOR). In addition, also through EPOR, pHBSP attenuated macrophage inflammatory activation and promoted PPAR\u03b3 expression. Furthermore, PPAR\u03b3 deficiency partly ablated the anti-inflammatory activity of pHBSP in macrophages. Correspondingly, pHBSP administration to high-fat diet (HFD)-fed mice significantly improved obesity, insulin resistance (IR) and adipose tissue inflammation without stimulating hematopoiesis. Therefore, pHBSP can significantly protect against obesity and IR partly by inhibiting adipogenesis and inflammation. These findings have therapeutic implications for metabolic disorders, such as obesity and diabetes.<\/jats:p>","DOI":"10.1038\/srep15134","type":"journal-article","created":{"date-parts":[[2015,10,13]],"date-time":"2015-10-13T09:49:50Z","timestamp":1444729790000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Nonerythropoietic Erythropoietin-Derived Peptide Suppresses Adipogenesis, Inflammation, Obesity and Insulin Resistance"],"prefix":"10.1038","volume":"5","author":[{"given":"Yuqi","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bangwei","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongchen","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinsong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zongwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shufeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiren","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,10,13]]},"reference":[{"key":"BFsrep15134_CR1","first-page":"1174","volume":"115","author":"R Vasilescu","year":"2011","unstructured":"Vasilescu, R. & Ionescu-Tirgoviste, C. [Association of albuminuria with adipokines, inflammation and insulin resistance in non-diabetic subjects]. Rev Med Chir Soc Med Nat Iasi 115, 1174\u20131182 (2011).","journal-title":"Rev Med Chir Soc Med Nat Iasi"},{"key":"BFsrep15134_CR2","doi-asserted-by":"publisher","first-page":"E1144","DOI":"10.1152\/ajpendo.2000.278.6.E1144","volume":"278","author":"JF Horowitz","year":"2000","unstructured":"Horowitz, J. F. & Klein, S. Whole body and abdominal lipolytic sensitivity to epinephrine is suppressed in upper body obese women. Am J Physiol Endocrinol Metab 278, E1144\u2013E1152 (2000).","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"BFsrep15134_CR3","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/nrm2391","volume":"9","author":"A Guilherme","year":"2008","unstructured":"Guilherme, A., Virbasius, J. V., Puri, V. & Czech, M. P. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 9, 367\u2013377 (2008).","journal-title":"Nat Rev Mol Cell Biol"},{"key":"BFsrep15134_CR4","doi-asserted-by":"publisher","first-page":"640673","DOI":"10.1155\/2013\/640673","volume":"2013","author":"C Lubrano","year":"2013","unstructured":"Lubrano, C. et al. Obesity and metabolic comorbidities: environmental diseases? OXID MED CELL LONGEV 2013, 640673 (2013).","journal-title":"OXID MED CELL LONGEV"},{"key":"BFsrep15134_CR5","unstructured":"Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 894, 1\u2013253 (2000)."},{"key":"BFsrep15134_CR6","doi-asserted-by":"publisher","first-page":"e1000324","DOI":"10.1371\/journal.pcbi.1000324","volume":"5","author":"J Jo","year":"2009","unstructured":"Jo, J. et al. Hypertrophy and\/or Hyperplasia: Dynamics of Adipose Tissue Growth. PLOS COMPUT BIOL 5, e1000324 (2009).","journal-title":"PLOS COMPUT BIOL"},{"key":"BFsrep15134_CR7","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S0092-8674(00)81359-8","volume":"87","author":"BM Spiegelman","year":"1996","unstructured":"Spiegelman, B. M. & Flier, J. S. Adipogenesis and obesity: rounding out the big picture. CELL 87, 377\u2013389 (1996).","journal-title":"CELL"},{"key":"BFsrep15134_CR8","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/ijo.2012.85","volume":"37","author":"SY Min","year":"2013","unstructured":"Min, S. Y. et al. Cocoa polyphenols suppress adipogenesis in vitro and obesity in vivo by targeting insulin receptor. Int J Obes (Lond) 37, 584\u2013592 (2013).","journal-title":"Int J Obes (Lond)"},{"key":"BFsrep15134_CR9","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1172\/JCI200319451","volume":"112","author":"H Xu","year":"2003","unstructured":"Xu, H. et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J CLIN INVEST 112, 1821\u20131830 (2003).","journal-title":"J CLIN INVEST"},{"key":"BFsrep15134_CR10","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1172\/JCI57132","volume":"121","author":"CN Lumeng","year":"2011","unstructured":"Lumeng, C. N. & Saltiel, A. R. Inflammatory links between obesity and metabolic disease. J CLIN INVEST 121, 2111\u20132117 (2011).","journal-title":"J CLIN INVEST"},{"key":"BFsrep15134_CR11","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.cmet.2006.11.005","volume":"4","author":"GR Steinberg","year":"2006","unstructured":"Steinberg, G. R. et al. Tumor necrosis factor alpha-induced skeletal muscle insulin resistance involves suppression of AMP-kinase signaling. CELL METAB 4, 465\u2013474 (2006).","journal-title":"CELL METAB"},{"key":"BFsrep15134_CR12","doi-asserted-by":"publisher","first-page":"7265","DOI":"10.1073\/pnas.1133870100","volume":"100","author":"P Sartipy","year":"2003","unstructured":"Sartipy, P. & Loskutoff, D. J. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci USA 100, 7265\u20137270 (2003).","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFsrep15134_CR13","first-page":"505","volume":"143","author":"RA Bastarrachea","year":"2007","unstructured":"Bastarrachea, R. A. et al. [Macrophages, inflammation, adipose tissue, obesity and insulin resistance]. GAC MED MEX 143, 505\u2013512 (2007).","journal-title":"GAC MED MEX"},{"key":"BFsrep15134_CR14","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/nm.2627","volume":"18","author":"O Osborn","year":"2012","unstructured":"Osborn, O. & Olefsky, J. M. The cellular and signaling networks linking the immune system and metabolism in disease. NAT MED 18, 363\u2013374 (2012).","journal-title":"NAT MED"},{"key":"BFsrep15134_CR15","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s00125-013-3145-0","volume":"57","author":"AE Hogan","year":"2014","unstructured":"Hogan, A. E. et al. Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus. DIABETOLOGIA 57, 781\u2013784 (2014).","journal-title":"DIABETOLOGIA"},{"key":"BFsrep15134_CR16","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1210\/jc.2006-1465","volume":"92","author":"M Kolak","year":"2007","unstructured":"Kolak, M., et al. Effects of chronic rosiglitazone therapy on gene expression in human adipose tissue in vivo in patients with type 2 diabetes. J Clin Endocrinol Metab 92, 720\u2013724 (2007).","journal-title":"J Clin Endocrinol Metab"},{"key":"BFsrep15134_CR17","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/ijo.2011.95","volume":"36","author":"SD Premaratna","year":"2012","unstructured":"Premaratna, S. D. et al. Angiotensin-converting enzyme inhibition reverses diet-induced obesity, insulin resistance and inflammation in C57BL\/6J mice. Int J Obes (Lond) 36, 233\u2013243 (2012).","journal-title":"Int J Obes (Lond)"},{"key":"BFsrep15134_CR18","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood.V77.3.419.419","volume":"77","author":"SBErythropoietin Krantz","year":"1991","unstructured":"Krantz, S.B. Erythropoietin. BLOOD 77, 419\u2013434 (1991).","journal-title":"BLOOD"},{"key":"BFsrep15134_CR19","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.mvr.2014.01.009","volume":"92","author":"BB Cokic","year":"2014","unstructured":"Cokic, B. B., Cokic, V. P., Suresh, S., Wirt, S. & Noguchi, C. T. Nitric oxide and hypoxia stimulate erythropoietin receptor via MAPK kinase in endothelial cells. MICROVASC RES 92, 34\u201340 (2014).","journal-title":"MICROVASC RES"},{"key":"BFsrep15134_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1741-7007-9-27","volume":"9","author":"D Sargin","year":"2011","unstructured":"Sargin, D. et al. Expression of constitutively active erythropoietin receptor in pyramidal neurons of cortex and hippocampus boosts higher cognitive functions in mice. BMC BIOL 9, 27 (2011).","journal-title":"BMC BIOL"},{"key":"BFsrep15134_CR21","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/nrn1687","volume":"6","author":"M Brines","year":"2005","unstructured":"Brines, M. & Cerami, A. Emerging biological roles for erythropoietin in the nervous system. NAT REV NEUROSCI 6, 484\u2013494 (2005).","journal-title":"NAT REV NEUROSCI"},{"key":"BFsrep15134_CR22","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/bjh.12105","volume":"160","author":"A Hara","year":"2013","unstructured":"Hara, A. et al. Autoantibodies to erythropoietin receptor in patients with immune-mediated diseases: relationship to anaemia with erythroid hypoplasia. Br J Haematol 160, 244\u2013250 (2013).","journal-title":"Br J Haematol"},{"key":"BFsrep15134_CR23","doi-asserted-by":"publisher","first-page":"4122","DOI":"10.2337\/db13-0518","volume":"62","author":"L Wang","year":"2013","unstructured":"Wang, L. et al. PPARalpha and Sirt1 mediate erythropoietin action in increasing metabolic activity and browning of white adipocytes to protect against obesity and metabolic disorders. DIABETES 62, 4122\u20134131 (2013).","journal-title":"DIABETES"},{"key":"BFsrep15134_CR24","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/ncomms1526","volume":"2","author":"R Teng","year":"2011","unstructured":"Teng, R. et al. Disrupted erythropoietin signalling promotes obesity and alters hypothalamus proopiomelanocortin production. NAT COMMUN 2, 520 (2011).","journal-title":"NAT COMMUN"},{"key":"BFsrep15134_CR25","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1159\/000356193","volume":"40","author":"W Jelkmann","year":"2013","unstructured":"Jelkmann, W. Physiology and pharmacology of erythropoietin. Transfus Med Hemother 40, 302\u2013309 (2013).","journal-title":"Transfus Med Hemother"},{"key":"BFsrep15134_CR26","doi-asserted-by":"publisher","first-page":"10925","DOI":"10.1073\/pnas.0805594105","volume":"105","author":"M Brines","year":"2008","unstructured":"Brines, M., et al. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci USA 105, 10925\u201310930 (2008).","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFsrep15134_CR27","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.2310\/JIM.0b013e3181ed30bf","volume":"59","author":"CC Hand","year":"2011","unstructured":"Hand, C. C. & Brines, M. Promises and pitfalls in erythopoietin-mediated tissue protection: are nonerythropoietic derivatives a way forward? J Investig Med 59, 1073\u20131082 (2011).","journal-title":"J Investig Med"},{"key":"BFsrep15134_CR28","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.neuroscience.2012.12.022","volume":"233","author":"KG Pulman","year":"2013","unstructured":"Pulman, K. G., Smith, M., Mengozzi, M., Ghezzi, P. & Dilley, A. The erythropoietin-derived peptide ARA290 reverses mechanical allodynia in the neuritis model. NEUROSCIENCE 233, 174\u2013183 (2013).","journal-title":"NEUROSCIENCE"},{"key":"BFsrep15134_CR29","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.pharmthera.2015.02.005","volume":"151","author":"M Collino","year":"2015","unstructured":"Collino, M., Thiemermann, C., Cerami, A. & Brines, M. Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin. Pharmacol Ther 151, 32\u201340 (2015).","journal-title":"Pharmacol Ther"},{"key":"BFsrep15134_CR30","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.2337\/db11-0026","volume":"60","author":"CM McVicar","year":"2011","unstructured":"McVicar, C. M. et al. Intervention with an erythropoietin-derived peptide protects against neuroglial and vascular degeneration during diabetic retinopathy. DIABETES 60, 2995\u20133005 (2011).","journal-title":"DIABETES"},{"key":"BFsrep15134_CR31","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.eplepsyres.2011.06.009","volume":"96","author":"C Zellinger","year":"2011","unstructured":"Zellinger, C. et al. Impact of the erythropoietin-derived peptide mimetic Epotris on the histopathological consequences of status epilepticus. EPILEPSY RES 96, 241\u2013249 (2011).","journal-title":"EPILEPSY RES"},{"key":"BFsrep15134_CR32","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1479-5876-11-9","volume":"11","author":"WG van Rijt","year":"2013","unstructured":"van Rijt, W. G. et al. ARA290, a non-erythropoietic EPO derivative, attenuates renal ischemia\/reperfusion injury. J TRANSL MED 11, 9 (2013).","journal-title":"J TRANSL MED"},{"key":"BFsrep15134_CR33","doi-asserted-by":"publisher","first-page":"e90942","DOI":"10.1371\/journal.pone.0090942","volume":"9","author":"Y Liu","year":"2014","unstructured":"Liu, Y., et al. Erythropoietin-derived nonerythropoietic peptide ameliorates experimental autoimmune neuritis by inflammation suppression and tissue protection. PLOS ONE 9, e90942 (2014).","journal-title":"PLOS ONE"},{"key":"BFsrep15134_CR34","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.2119\/molmed.2012.00332","volume":"18","author":"L Heij","year":"2012","unstructured":"Heij, L. et al. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. MOL MED 18, 1430\u20131436 (2012).","journal-title":"MOL MED"},{"key":"BFsrep15134_CR35","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1073\/pnas.0137044100","volume":"100","author":"QQ Tang","year":"2003","unstructured":"Tang, Q. Q., Otto, T. C. & Lane, M. D. Mitotic clonal expansion: a synchronous process required for adipogenesis. Proc Natl Acad Sci USA 100, 44\u201349 (2003).","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFsrep15134_CR36","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1210\/mend.11.13.0027","volume":"11","author":"LN Cong","year":"1997","unstructured":"Cong, L. N. et al. Physiological role of Akt in insulin-stimulated translocation of GLUT4 in transfected rat adipose cells. MOL ENDOCRINOL 11, 1881\u20131890 (1997).","journal-title":"MOL ENDOCRINOL"},{"key":"BFsrep15134_CR37","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1093\/carcin\/bgg060","volume":"24","author":"Y Yasuda","year":"2003","unstructured":"Yasuda, Y. et al. Erythropoietin regulates tumour growth of human malignancies. CARCINOGENESIS 24, 1021\u20131029 (2003).","journal-title":"CARCINOGENESIS"},{"key":"BFsrep15134_CR38","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.2337\/db13-0883","volume":"63","author":"M Alnaeeli","year":"2014","unstructured":"Alnaeeli, M. et al. Erythropoietin signaling: a novel regulator of white adipose tissue inflammation during diet-induced obesity. DIABETES 63, 2415\u20132431 (2014).","journal-title":"DIABETES"},{"key":"BFsrep15134_CR39","doi-asserted-by":"publisher","first-page":"373781","DOI":"10.1155\/2011\/373781","volume":"2011","author":"A Foskett","year":"2011","unstructured":"Foskett, A., Alnaeeli, M., Wang, L., Teng, R. & Noguchi, C. T. The effects of erythropoietin dose titration during high-fat diet-induced obesity. J Biomed Biotechnol 2011, 373781 (2011).","journal-title":"J Biomed Biotechnol"},{"key":"BFsrep15134_CR40","doi-asserted-by":"publisher","first-page":"e5894","DOI":"10.1371\/journal.pone.0005894","volume":"4","author":"P Hojman","year":"2009","unstructured":"Hojman, P., et al. Erythropoietin over-expression protects against diet-induced obesity in mice through increased fat oxidation in muscles. PLOS ONE 4, e5894 (2009).","journal-title":"PLOS ONE"},{"key":"BFsrep15134_CR41","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ijcard.2013.12.011","volume":"171","author":"F Sanchis-Gomar","year":"2014","unstructured":"Sanchis-Gomar, F. et al. Erythropoietin and the heart: physiological effects and the therapeutic perspective. INT J CARDIOL 171, 116\u2013125 (2014).","journal-title":"INT J CARDIOL"},{"key":"BFsrep15134_CR42","doi-asserted-by":"publisher","first-page":"5802","DOI":"10.1111\/bph.12888","volume":"171","author":"M Collino","year":"2014","unstructured":"Collino, M. et al. A non-erythropoietic peptide derivative of erythropoietin decreases susceptibility to diet-induced insulin resistance in mice. Br J Pharmacol 171, 5802\u20135815 (2014).","journal-title":"Br J Pharmacol"},{"key":"BFsrep15134_CR43","doi-asserted-by":"publisher","first-page":"658","DOI":"10.2119\/molmed.2014.00215","volume":"20","author":"M Brines","year":"2015","unstructured":"Brines, M. et al. ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes. MOL MED 20, 658\u2013666 (2015).","journal-title":"MOL MED"},{"key":"BFsrep15134_CR44","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1126\/science.288.5475.2379","volume":"288","author":"TM Loftus","year":"2000","unstructured":"Loftus, T. M. et al. Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. SCIENCE 288, 2379\u20132381 (2000).","journal-title":"SCIENCE"},{"key":"BFsrep15134_CR45","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1055\/s-0032-1301901","volume":"44","author":"E Mikolas","year":"2012","unstructured":"Mikolas, E. et al. Effects of erythropoietin on glucose metabolism. HORM METAB RES 44, 279\u2013285 (2012).","journal-title":"HORM METAB RES"},{"key":"BFsrep15134_CR46","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3389\/fendo.2013.00071","volume":"4","author":"H Kwon","year":"2013","unstructured":"Kwon, H. & Pessin, J. E. Adipokines mediate inflammation and insulin resistance. Front Endocrinol (Lausanne) 4, 71 (2013).","journal-title":"Front Endocrinol (Lausanne)"},{"key":"BFsrep15134_CR47","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1172\/JCI119715","volume":"100","author":"P Peraldi","year":"1997","unstructured":"Peraldi, P., Xu, M. & Spiegelman, B. M. Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling. J CLIN INVEST 100, 1863\u20131869 (1997).","journal-title":"J CLIN INVEST"},{"key":"BFsrep15134_CR48","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/39335","volume":"389","author":"KT Uysal","year":"1997","unstructured":"Uysal, K. T., Wiesbrock, S. M., Marino, M. W. & Hotamisligil, G. S. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. NATURE 389, 610\u2013614 (1997).","journal-title":"NATURE"},{"key":"BFsrep15134_CR49","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.bbrc.2003.10.013","volume":"311","author":"C Lagathu","year":"2003","unstructured":"Lagathu, C. et al. Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. Biochem Biophys Res Commun 311, 372\u2013379 (2003).","journal-title":"Biochem Biophys Res Commun"},{"key":"BFsrep15134_CR50","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1172\/JCI26498","volume":"116","author":"H Kanda","year":"2006","unstructured":"Kanda, H. et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance and hepatic steatosis in obesity. J CLIN INVEST 116, 1494\u20131505 (2006).","journal-title":"J CLIN INVEST"},{"key":"BFsrep15134_CR51","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1097-2765(00)80210-5","volume":"4","author":"N Kubota","year":"1999","unstructured":"Kubota, N. et al. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. MOL CELL 4, 597\u2013609 (1999).","journal-title":"MOL CELL"},{"key":"BFsrep15134_CR52","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1172\/JCI8538","volume":"105","author":"PD Miles","year":"2000","unstructured":"Miles, P. D., Barak, Y., He, W., Evans, R. M. & Olefsky, J. M. Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. J CLIN INVEST 105, 287\u2013292 (2000).","journal-title":"J CLIN INVEST"},{"key":"BFsrep15134_CR53","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/nm.3159","volume":"19","author":"M Ahmadian","year":"2013","unstructured":"Ahmadian, M. et al. PPARgamma signaling and metabolism: the good, the bad and the future. NAT MED 19, 557\u2013566 (2013).","journal-title":"NAT MED"},{"key":"BFsrep15134_CR54","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/83336","volume":"7","author":"A Chawla","year":"2001","unstructured":"Chawla, A. et al. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. NAT MED 7, 48\u201352 (2001).","journal-title":"NAT MED"},{"key":"BFsrep15134_CR55","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1093\/cvr\/cvs125","volume":"94","author":"T Neri","year":"2012","unstructured":"Neri, T. et al. Effects of peroxisome proliferator-activated receptor-gamma agonists on the generation of microparticles by monocytes\/macrophages. CARDIOVASC RES 94, 537\u2013544 (2012).","journal-title":"CARDIOVASC RES"},{"key":"BFsrep15134_CR56","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1126\/science.274.5295.2100","volume":"274","author":"E Hu","year":"1996","unstructured":"Hu, E., Kim, J. B., Sarraf, P. & Spiegelman, B. M. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma. SCIENCE 274, 2100\u20132103 (1996).","journal-title":"SCIENCE"},{"key":"BFsrep15134_CR57","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.immuni.2011.01.002","volume":"34","author":"M Nairz","year":"2011","unstructured":"Nairz, M. et al. Erythropoietin contrastingly affects bacterial infection and experimental colitis by inhibiting nuclear factor-kappaB-inducible immune pathways. IMMUNITY 34, 61\u201374 (2011).","journal-title":"IMMUNITY"},{"key":"BFsrep15134_CR58","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1074\/jbc.M004885200","volume":"276","author":"J Hu","year":"2001","unstructured":"Hu, J. et al. ERK1 and ERK2 activate CCAAAT\/enhancer-binding protein-beta-dependent gene transcription in response to interferon-gamma. J BIOL CHEM 276, 287\u2013297 (2001).","journal-title":"J BIOL CHEM"},{"key":"BFsrep15134_CR59","doi-asserted-by":"publisher","first-page":"52543","DOI":"10.1074\/jbc.M405189200","volume":"279","author":"A Nonami","year":"2004","unstructured":"Nonami, A. et al. Spred-1 negatively regulates interleukin-3-mediated ERK\/mitogen-activated protein (MAP) kinase activation in hematopoietic cells. J BIOL CHEM 279, 52543\u201352551 (2004).","journal-title":"J BIOL CHEM"},{"key":"BFsrep15134_CR60","doi-asserted-by":"publisher","first-page":"46226","DOI":"10.1074\/jbc.M207776200","volume":"277","author":"D Prusty","year":"2002","unstructured":"Prusty, D., Park, B. H., Davis, K. E. & Farmer, S. R. Activation of MEK\/ERK signaling promotes adipogenesis by enhancing peroxisome proliferator-activated receptor gamma (PPARgamma) and C\/EBPalpha gene expression during the differentiation of 3T3-L1 preadipocytes. J BIOL CHEM 277, 46226\u201346232 (2002).","journal-title":"J BIOL CHEM"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep15134.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep15134","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep15134.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T15:32:32Z","timestamp":1672932752000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep15134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,13]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,12,7]]}},"alternative-id":["BFsrep15134"],"URL":"https:\/\/doi.org\/10.1038\/srep15134","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,13]]},"assertion":[{"value":"13 November 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15134"}}